The Dutch biotech Crucell will pocket a €10 million up front payment and up to €66.5 million in milestone payments after forging a collaboration and marketing deal with Sanofi Pasteur for its rabies monoclonal antibodies. Sanofi Pasteur has a well developed market for vaccines to combat pre- and post-exposure rabies.
"Adding a next generation rabies treatment to our well-established rabies product range will further position the company as a leading force to help prevent this fatal disease," said Wayne Pisano, the CEO of Sanofi Pasteur. The deal was announced this morning.
- see this release
- read the report from Thomson Financial